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Slit- and Trk-like (Slitrks) are a six-member family of synapse organizers that control
excitatory and inhibitory synapse formation by forming trans-synaptic adhesions with
LAR receptor protein tyrosine phosphatases (PTPs). Intriguingly, genetic mutations of
Slitrks have been associated with a multitude of neuropsychiatric disorders. However,
nothing is known about the neuronal and synaptic consequences of these mutations.
Here, we report the structural and functional effects on synapses of various rare de novo
mutations identified in patients with schizophrenia or Tourette syndrome. A number of
single amino acid substitutions in Slitrk1 (N400I or T418S) or Slitrk4 (V206I or I578V)
reduced their surface expression levels. These substitutions impaired glycosylation of
Slitrks expressed in HEK293T cells, caused retention of Slitrks in the endoplasmic
reticulum and cis-Golgi compartment in COS-7 cells and neurons, and abolished Slitrk
binding to PTPδ. Furthermore, these substitutions eliminated the synapse-inducing
activity of Slitrks, abolishing their functional effects on synapse density in cultured
neurons. Strikingly, a valine-to-methionine mutation in Slitrk2 (V89M) compromised
synapse formation activity in cultured neuron, without affecting surface transport,
expression, or synapse-inducing activity in coculture assays. Similar deleterious effects
were observed upon introduction of the corresponding valine-to-methionine mutation
into Slitrk1 (V85M), suggesting that this conserved valine residue plays a key role
in maintaining the synaptic functions of Slitrks. Collectively, these data indicate that
inactivation of distinct cellular mechanisms caused by specific Slitrk dysfunctions may
underlie Slitrk-associated neuropsychiatric disorders in humans, and provide a robust
cellular readout for the development of knowledge-based therapies.
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INTRODUCTION
Neuropsychiatric disorders such as schizophrenia, autism spectrum disorders (ASDs), and
Tourette syndrome usually comprise heterogeneous and complex clinical syndromes with
largely unknown etiologies (State, 2011; State and Levitt, 2011). Although epidemiological and
descriptive studies have attempted to formulate etiological hypotheses to account for a subset of
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neuropsychiatric disorders, genetic studies have clearly
demonstrated the high heritability of these disorders, albeit
with complex inheritance pattern (Heinzen et al., 2015). To
further complicate matters, genetic causation can range from a
simple point mutation in a single gene to polygenetic causes that
enlist an unknown mode of inheritance, incomplete penetrance,
variable expressivity, epistasis, and/or etiological heterogeneity
(Heinzen et al., 2015). Faced with this daunting challenge,
researchers seeking to attain the conceptual advances necessary
to design effective and precise therapeutics, critically require
a more detailed comprehension of brain function (Insel and
Landis, 2013). Rapid advances in human genome sequencing
techniques have contributed significantly to the elucidation
of candidate genes that are highly associated with a variety
of neuropsychiatric disorders (Medland et al., 2014; Heinzen
et al., 2015). In particular, large-scale, genome-wide association
studies of patients suffering from various neuropsychiatric
diseases have identified copy number variants, single-
nucleotide polymorphisms and a variety of point mutations
(State, 2011; State and Levitt, 2011; Heinzen et al., 2015).
Intriguingly, a number of synaptic genes have frequently been
identified as susceptibility factors, supporting the well-accepted
‘synaptopathy’ hypothesis, which posits that distinct synaptic
dysfunctions constitute core features of various neuropsychiatric
disorders (Brose et al., 2010). Not surprisingly, a host of synaptic
adhesion molecules (e.g., neurexins and neuroligins) have been
recognized as candidate contributors to various neuropsychiatric
disorders, given their central importance in synaptic functions
(Sudhof, 2008; Missler et al., 2012; Ko J. et al., 2015). However,
how dysfunctions of most synaptic proteins lead to these
devastating disorders remains poorly understood. In particular,
why identical genetic factors are commonly found in clinically
separable neuropsychiatric disorders, a finding that could
account for the high comorbidity of a subset of brain disorders
(Keezer and Sander, 2016; Keezer et al., 2016), has remained
puzzling.
Slit- and Trk-like (Slitrk) proteins constitute a family
of leucine-rich repeat (LRR)-containing synaptic adhesion
molecules that are highly expressed in the central nervous system
(Aruga and Mikoshiba, 2003; Aruga et al., 2003; Beaubien and
Cloutier, 2009; de Wit et al., 2011; Ko, 2012). They possess
a common structural architecture composed of tandem LRR
domains (LRR1 and LRR2), a single transmembrane domain, and
a divergent cytoplasmic region (Aruga and Mikoshiba, 2003).
Functionally, they control excitatory and inhibitory synapse
formation by interacting with LAR-RPTPs (leukocyte common
antigen-related receptor protein tyrosine phosphatases, PTP)
through the LRR1 domain (Takahashi et al., 2012; Um and Ko,
2013; Yim et al., 2013; Han et al., 2016a; see Um et al., 2014a,
for complex structure). Slitrk3 specifically regulates inhibitory
synapse development through binding to PTPδ, whereas other
Slitrks organize excitatory synapse development through binding
to PTPσ (Takahashi et al., 2012; Yim et al., 2013). Like other
synaptic adhesion proteins, a subset of Slitrk point mutants
have been linked to schizophrenia, ASDs, Tourette syndrome,
or obsessive−compulsive disorder (OCD; reviewed in Ko, 2012;
Um and Ko, 2013). For example, Slitrk1 has been postulated to
be causative for Tourette syndrome (Abelson et al., 2005; Grados
and Walkup, 2006), although subsequent studies (Keen-Kim and
Freimer, 2006; Chou et al., 2007; Fabbrini et al., 2007; Scharf
et al., 2008) have questioned the validity of conclusions reached
by these earlier studies (Keen-Kim and Freimer, 2006; Chou et al.,
2007; Fabbrini et al., 2007; Scharf et al., 2008). Moreover, several
non-synonymous, rare variants of Slitrk1, Slitrk2, and Slitrk4
were recently reported to be associated with schizophrenia or
OCD spectrum disorders (Zuchner et al., 2006; Piton et al., 2011;
Ozomaro et al., 2013). However, it remains to be determined
whether these mutations are functionally significant or represent
benign polymorphisms.
Here, we systematically investigated the effects of four
Slitrk1, five Slitrk2, and two Slitrk4 missense mutations
on biochemical properties, surface transport, ligand-binding
activity, and synaptogenic activities in cultured hippocampal
neurons. We show that a subset of Slitrk1 (N400I and T418S)
and Slitrk4 (V206I and I578V) mutations impair the biochemical
and cell-biological properties of the corresponding wild-type
(WT) Slitrks, through a common loss-of-function mechanism
that basically traps them intracellularly, blocking their surface
transport and ligand binding, and abolishing their synapse-
promoting activity. By comparison, a Slitrk2 V89M mutation
did not alter any of these parameters; instead it acted through
a gain-of-function mechanism to compromise the ability of
WT Slitrk2 to restore deficits in synapse density observed in
Slitrk2-deficient neurons. Intriguingly, the analogous Slitrk1
point mutant (Slitrk1[V85M]) also displayed an impaired ability
to rescue synaptogenic deficits in Slitrk1-deficient neurons. Our
data reveal the underlying mechanisms by which a subset of Slitrk
missense mutations observed in patients with neuropsychiatric
disorders induce distinct gain- and loss-of-function phenotypes,
and may provide a partial correlation with the clinical phenotypes
shown in Slitrk dysfunction-associated disorders.
MATERIALS AND METHODS
In silico Analysis
Previously identified Slitrk missense mutations implicated in
neuropsychiatric disorders were analyzed using four different
prediction programs. (1) PolyPhen-2, available via the Web
server1, predicts the functional significance of an allele
replacement from its individual features employing a Naïve
Bayes classifier, trained using supervised machine learning.
Mutations whose posterior probability scores are associated
with estimated false-positive rates (FPR) at or below the first
(lower) FPR are predicted to be ‘probably damaging’. Mutations
with posterior probabilities associated with FPR at or below the
second (higher) FPR are predicted to be ‘possibly damaging’.
Mutations with an estimated FPR above the second (higher)
FPR value are classified as ‘benign’. (2) PROVEAN (Protein
Variation Effect Analyzer), available via the Web server2,
clusters BLAST hits using its CD-HIT module based on a global
1http://genetics.bwh.harvard.edu/pph2/
2http://provean.jcvi.org/index.php
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FIGURE 1 | Alignment and conservation across different species of Slitrk1, Slitrk2, and Slitrk4 (Slit- and Trk-like) residues that are mutated in human
patients with schizophrenia, Tourette syndrome, or trichotillomania. (A–C) Alignment of human Slitrk amino acids surrounding the mutated residues found in
(Continued)
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 October 2016 | Volume 9 | Article 104
fnmol-09-00104 October 18, 2016 Time: 14:46 # 4
Kang et al. Slitrk Mutations Implicated in Brain Disorders
FIGURE 1 | Continued
human patients with neuropsychiatric disorders. The target mutated resides are indicated in bold. Schematic drawings of the entire domain organization
of human Slitrk1 (A), Slitrk2 (B), and Slitrk4 (C) are shown. (D−F) Similarity or identity of mutated residues investigated in the current study was determined
by analyzing the amino acid sequences of human Slitrk1 (D), Slitrk2 (E), and Slitrk4 (F) deposited in the National Center for Biotechnology Information (NCBI) database.
Identical residues across various species are indicated in yellow letters on a black background. The following GenBank accession numbers were
utilized for sequence alignment: Slitrk1/human, NP_443142; Slitrk1/gorilla, XP_004054683; Slitrk1/macaque, NP_001247716; Slitrk1/bovine, XP_002691955;
Slitrk1/sheep, XP_004012247; Slitrk1/mouse, EDL00537; Slitrk1/rat, NP_001100753; Slitrk1/dog, XP_542628; Slitrk1/zebrafish, XP_687093; Slitrk1/chicken,
XP_416993; Slitrk2/human, NP_001137482; Slitrk2/gorilla, XP_004065021; Slitrk2/macaque, NP_001248149; Slitrk2/bovine, XP_015325702; Slitrk2/sheep,
XP_004022343; Slitrk2/pig, XP_013841934; Slitrk2/rat, NP_001101057; Slitrk2/mouse, AAI12407; Slitrk2/dog, XP_013967295; Slitrk2/bird, XP_012428589;
Slitrk2/chicken, XP_420364; Slitrk4/human, NP_001171679; Slitrk4/gorilla, XP_004065019; Slitrk4/macaque, XP_001086308; Slitrk4/bovine, XP_005227618;
Slitrk4/sheep, XP_004022346; Slitrk4/rat, NP_001100417; Slitrk4/mouse, AAI17892; Slitrk4/dog, XP_005641950; Slitrk4/bird, XP_012428616; and Slitrk4/chicken,
XP_015134020.
TABLE 1 | Prediction of functional effect of Slit- and Trk-like (Slitrk) mutations using four different bioinformatics tools.
Gene amino acid change Cohort PolyPhen-2 PROVEAN Mutation
Assessor
PANTHER Reference
SubPSEC Score Pdeleterious
Slitrk1 V85M n.a. Possibly damaging
(0.855)
Neutral
(−0.968)
Medium (2.31) n.d. n.d. This study
Slitrk1 N400I TS Benign (0.162) Deleterious
(−2.943)
Low (1.93) −2.40948 0.35652 Ozomaro et al., 2013
Slitrk1 T418S TS Benign (0.115) Neutral
(−0.274)
Neutral (0.505) n.d. n.d. Ozomaro et al., 2013
Slitrk1 R584K TTM Benign (0) Neutral (0.220) Neutral
(−0.485)
−0.25178 0.06019 Zuchner et al., 2006
Slitrk1 S593G TTM Benign (0.014) Neutral
(−1.596)
Medium (2.28) −1.94135 0.25757 Zuchner et al., 2006
Slitrk2 R32L SCZ Benign (0.035) Neutral (0.487) Neutral (0.415) n.d. n.d. Piton et al., 2011
Slitrk2 V89M SCZ Probably damaging
(0.984)
Neutral
(−0.932)
Low (1.545) −2.59958 0.40121 Piton et al., 2011
Slitrk2 S549F SCZ Benign (0.203) Deleterious
(−2.957)
Low (0.985) −3.12094 0.5302 Piton et al., 2011
Slitrk2 S601P ASD Benign (0) Neutral
(−0.205)
Neutral (0.5) −1.47548 0.1788 Piton et al., 2011
Slitrk2 L626F SCZ Probably damaging
(1)
Deleterious
(−2.780)
Medium (1.975) n.d. n.d. Piton et al., 2011
Slitrk4 V206I SCZ Probably damaging
(0.998)
Neutral
(−0.404)
Neutral (0.6) n.d. n.d. Piton et al., 2011
Slitrk4 I578V SCZ Benign (0.012) Neutral (0.173) Neutral (0.425) n.d. n.d. Piton et al., 2011
ASD, Autism spectrum disorder; n.a., not applicable; n.d., not determined; PANTHER, Protein Analysis Through Evolutionary Relationships; PolyPhen-2, Polymorphism
Phenotyping v2; PROVEAN, Protein Variation Effect Analyzer; SCZ, Schizophrenia; SIFT, Sorting Intolerant From Tolerant; TS, Tourette’s syndrome; TTM, Trichotillomania.
sequence identity parameter of 75%. The supporting sequence
set, representing the top 30 clusters of closely related sequences,
is used to generate predictions. For each supporting sequence,
a delta alignment score is computed and used to determine
the PROVEAN score. If the PROVEAN score is less than or
equal to −2.5 (predefined threshold), the protein variant is
considered ‘deleterious’; variants with scores greater than −2.5
are considered ‘neutral’. (3) MutationAssessor was automatically
run using the Web server3, as previously described (Reva et al.,
2011). (4) PANTHER (Protein Analysis Through Evolutionary
Relationships), available through the Web server4, generates
SubPSEC scores, which are continuous values from 0 (neutral)
to about −10 (most likely deleterious). A Pdeleterious value of 0.5
3http://mutationassessor.org/r3/
4http://www.pantherdb.org/tools/
corresponds to a SubPSEC score of −3. The probability that a
given variant will cause a deleterious effect on protein function
is estimated from Pdeleterious such that a SubPSEC score of −3
corresponds to a Pdeleterious of 0.5 (Mi et al., 2016). ‘n.d.’ in
PANTHER indicates that the position does not align to Hidden
Markov Model (HMM) libraries.
Structural Modeling
Structures of human Slitrk2 (LRR1, aa D27–P264; and LRR2, aa
S342–P579) and human Slitrk4 (LRR1, aa N28–P64; and LRR2,
aa P343–P581) were modeled through the SWISS-MODEL server
using human Sltirk1 LRR1 (PDB ID: 4RCA), mouse Slitrk2 LRR1
(PDB ID: 4Y61), and human Slitrk1 LRR2 (PDB ID: 4RCW)
as templates. All drawings depicting molecular structures were
prepared using PyMOL (PyMOL Molecular Graphics System)
(Um et al., 2014a).
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FIGURE 2 | Structural modeling of Slitrk1, Slitrk2, and Slitrk4 residues that are mutated in human patients. Overall structures of LRR1 and LRR2 domains
of human Slitrk1, Slitrk2 and Slitrk4 (left). The crystal structure of human Slitrk1 LRR1/human PTPδ Ig1-3 complex (PDB ID: 4RCA) and human Slitrk1 LRR2 (PDB ID:
4RCW) were used for presenting the structures of human Slitrk1 LRR1 and LRR2. The structure of human Slitrk2 and Slitrk4 were modeled with SWISS-MODEL
server. The residues corresponding to patients’ mutations described in the current study are presented as red sticks in the cartoon presentation. Human Slitrk1,
Slitrk2, and Slitrk4 are colored gray, cyan and purple, respectively. Yellow dotted regions in the LRR1 domains of Slitrks indicate the LAR-RPTP binding surfaces
based on the 3D structure of the human Slitrk1 LRR1/PTPδ Ig1-3 complex (PDB ID: 4RCA), and black dotted lines represent flexible linkers between LRR1 and
LRR2 domains (left). Close-up views of mutated and neighboring residues in LRR domains (right).
Construction of Expression Vectors
pDisplay-Slitrk1 mutants (V85M, N400I, T418S, R584K,
S593G), pDisplay-Slitrk2 mutants (R32L, V89M, S549F,
S601P, L626F), and pDisplay-Slitrk4 mutants (V206I,
I578V) were generated with a site-directed mutagenesis kit
(Stratagene) using the corresponding WT pDisplay constructs
as templates. The following constructs were previously
described: pDisplay-Slitrk1 WT, pDisplay-Slitrk2 WT,
pDisplay-Slitrk4 WT, L-315 sh-Slitrk1, L-315 sh-Slitrk2, and
L-315 sh-Slitrk4 (Yim et al., 2013); and pVL1393-PTPδ (Um
et al., 2014a). The BFP-KDEL vector was purchased from
Addgene (construct #49150).
Antibodies
The following antibodies were obtained from the indicated
commercial sources: mouse monoclonal anti-HA (clone
HA-7; Covance), rabbit polyclonal anti-HA (H6908; Sigma),
mouse monoclonal anti-α-tubulin (clone DM1A; Sigma),
rabbit polyclonal anti-actin (A2066; Sigma), goat polyclonal
anti-EGFP (Rockland), and mouse monoclonal anti-GM130
(clone 35/GM130; BD Transduction Laboratories). The anti-
synapsin antibody was previously described (Han et al.,
2016b).
Heterologous Synapse-Formation Assay
Heterologous synapse-formation assays were performed using
HEK293T cells as previously described (Ko et al., 2009; Um et al.,
2014b). In brief, HEK293T cells were cotransfected with EGFP
or HA-Slitrk1 WT, HA-Slitrk1 point mutants, HA-Slitrk2 WT,
HA-Slitrk2 point mutants, HA-Slitrk4 WT, or HA-Slitrk4 point
mutants (described in ‘Construction of expression vectors’) using
the FuGene reagent (Roche). After 48 h, transfected HEK293T
cells were trypsinized and seeded onto DIV9 hippocampal
neuron cultures. Cells were further cocultured for 72 h and
then double-immunostained with anti-HA and anti-synapsin
antibodies at DIV12 as described previously (Ko J.S. et al.,
2015). All images were acquired with a confocal microscope. For
quantifications, the contours of transfected HEK293T cells were
chosen as the region of interest. The fluorescence intensity of
synapsin puncta normalized to the area of each HEK293T cell
was quantified for both red and green channels using MetaMorph
Software (Molecular Devices).
Glycosylation Assay
Solubilized proteins from HEK293T cells transfected with
expression plasmids for WT or mutant Slitrks, were first
denatured by adding 10x denaturing buffer (New England
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FIGURE 3 | Impaired glycosylation and surface trafficking of a subset of Slitrk mutations. (A) Representative immunoblot images from HEK293T cells
transfected with the indicated WT or mutant forms of HA-tagged Slitrk1, Slitrk2, or Slitrk4. Samples containing equal amounts of protein were resolved by
SDS-PAGE and immunoblotted using anti-HA antibodies; α-tubulin was used for normalization. Molecular mass markers are labeled in kilodaltons. (B) Immunoblot
analysis of Endo-H and PNGase F enzyme-digested lysates of HEK293T cells expressing WT HA-tagged Slitrk; α-tubulin or actin was used for normalization.
Molecular mass markers are labeled in kilodaltons. (C−E) Surface expression analysis of HEK293T cells expressing WT or point mutant forms of HA-tagged Slitrk1
(Continued)
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FIGURE 3 | Continued
(C), Slitrk2 (D), or Slitrk4 (E). Transfected cells were immunostained with mouse anti-HA antibodies (red) and detected with Cy3-conjugated anti-mouse
secondary antibodies under non-permeabilized conditions, followed by permeabilization of cells. Cells were then stained first with rabbit anti-HA antibodies (green)
and then with FITC-conjugated anti-rabbit secondary antibodies. Scale bar, 10 µm (applies to all images). (F) Quantification of the proportion of cells exhibiting
surface expression of Slitrks. All data are shown as means ± SEMs (2∗p < 0.01; 3∗p < 0.001; ANOVA with post hoc Tukey’s test; p-value of WT Slitrk1 vs
Slitrk1[N400I] = 0.000033; p-value of WT Slitrk1 vs Slitrk1[T418S] = 0.000065; p-value of WT Slitrk1 vs. Slitrk1[R584K] = 0.259; p-value of WT
Slitrk1 vs. Slitrk1[S593G] = 0.34; p-value of WT Slitrk2 vs. Slitrk2[R32L] = 0.941; p-value of WT Slitrk2 vs. Slitrk2[V89M] = 0.948; p-value of WT Slitrk2
vs. Slitrk2[S549F] = 0.988; p-value of WT Slitrk2 vs. Slitrk2[S601P] = 0.997; p-value of WT Slitrk2 vs. Slitrk2[L626F] = 0.996; p-value of WT Slitrk4 vs.
Slitrk4[V206I] = 0.000677; p-value of WT Slitrk4 vs. Slitrk4[I578V] = 0.003946). The numbers of cells counted (n) were as follows: WT Slitrk1, n = 360;
Slitrk1[N400I], n = 327; Slitrk1[T418S], n = 412; Slitrk1[R584K], n = 496; Slitrk1[S593G], n = 333; WT Slitrk2, n = 345; Slitrk2[R32L], n = 321; Slitrk2[V89M],
n = 371; Slitrk2[S549F], n = 360; Slitrk2[S601P], n = 313; Slitrk2[L626F], n = 319; WT Slitrk4, n = 256; Slitrk4[V206I], n = 181; and Slitrk4[I578V], n = 161.
(G) Slitrk surface exposure on transfected HEK293T cells, analyzed by immunoblotting of affinity-purified, surface-biotinylated Slitrk proteins. Biotinylated cell surface
proteins (S) and total lysate proteins (I) were assessed by immunoblot with anti-HA antibodies. Input, 5% of total lysates used in biotinylation experiments. Note that
mutants of Slitrk1 (N400I and T418S) and Slitrk4 (V206I and I578V) exhibit impaired surface expression, as similarly observed in (C−F).
Biolabs) and heating to 100◦C for 10 min. For endoglycosidase H
(Endo H) treatment, denatured protein was treated with 1 µl of
enzyme and incubated at 37◦C for 1 h. For PNGase F treatment,
denatured protein was incubated with 1 µl of enzyme in the
presence of 2 µl of NP-40 (100%) at 37◦C for 1 h. Thereafter,
enzyme-treated proteins, together with an equal amount of
untreated proteins, were analyzed by immunoblotting with the
indicated antibodies followed by enhanced chemiluminescence
(ECL) detection.
Biotinylation Assay
Biotinylation experiments in HEK293T cells were performed as
previously described (Han et al., 2016b). Briefly, HEK293T cells
transfected with the indicated Slitrk plasmids were washed three
times with ice-cold PBS containing 1 mM MgCl2 and 1 mM
CaCl2. Sulfo-NHS-LC-biotin (1 mg/ml) was then added, and cells
were kept at 4◦C for 30 min. After incubation, cells were washed
three times with PBS plus 100 mM glycine to quench and remove
excess biotin. Purified membrane proteins were then incubated
with Neutravidin (Thermo Scientific) overnight at 4◦C. After
three washes with PBS, proteins were eluted with sample buffer
and analyzed by immunoblotting.
Primary Neuronal Culture, Transfection,
and Immunocytochemistry
Rat hippocampal cultures were prepared from embryonic day
18 (E18) embryos as described previously (Ko et al., 2011;
Um et al., 2016). All experimental protocols using pregnant
rats were approved by the Institutional Animal Care and Use
Committee of Yonsei University College of Medicine. For
overexpression, hippocampal neurons were transfected with
various Slitrks vector using CalPhos Kit (Clontech) at DIV10
and immunostained at DIV14. For knockdown of Slitrk1,
Slitrk2, or Slitrk4, hippocampal neurons were co-transfected
with the corresponding L-315 sh-Slitrk vector at DIV8 and
immunostained at DIV14, as indicated in the figure legends.
For immunocytochemistry, cultured neurons were first fixed
with 4% paraformaldehyde/4% sucrose for 10 minutes at room
temperature and then permeabilized with 0.2% Triton X-100
in PBS for 5 min at 4◦C. Fixed, permeabilized neurons were
then blocked by incubating with 3% horse serum/0.1% crystalline
grade bovine serum albumin (BSA) in PBS for 30 min at room
temperature, and incubated with the indicated primary and
secondary antibodies in blocking solution for 1 h each at room
temperature.
Neurite Outgrowth Assay
Hippocampal neurons prepared from E18 rat embryo were
transfected with WT Slitrk, Slitrk[N400I] or Slitrk[T418S]
together with pEGFP-N1 vector at DIV3 and immunostained
with anti-EGFP antibodies at DIV6. Fluorescent images of
neurons were randomly captured and neurite length was
analyzed using MetaMorph software (Molecular Devices).
Confocal Microscopy Image Acquisition
and Analysis
Transfected neurons were randomly chosen and acquired at
constant imaging settings using a confocal microscope (LSM700;
Carl Zeiss) with a 63× objective lens. Z-stack images obtained
at 0.1µm intervals by confocal microscopy were converted to
maximal projections, and the size and density of presynaptic
terminals were analyzed using MetaMorph software. All images
were separated into different color channels (red and green),
and red-colored images were transformed into an image in
grayscale mode using Photoshop (Adobe). After selecting one
or two primary dendrites from neurons in a single image frame,
dendrite lengths were recorded and dendritic regions of interest
were manually traced in MetaMorph software and saved for
puncta measurements (in rgn file format). A constant intensity
threshold that excluded diffuse nonsynaptic signals but included
synaptic signals (90; range, 0–255) was applied to all gray
images. The saved dendritic regions were loaded, calibrated,
and measured using the ‘integrated morphometry analysis’
option. The linear density of synapsin clusters was determined
from calculated total puncta numbers, normalized to 10 µm
length of dendrite. For puncta size and intensity measurements,
normalized puncta areas and averaged puncta intensities were
calculated and exported automatically to the Excel program
(Microsoft). All quantitative analyses were performed in a
blinded manner.
Statistics
All data are expressed as means ± SEM. All statistical analyses
were performed using SPSS Statistics 23 (IBM, Armonk, NY,
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FIGURE 4 | Characterization of LAR-RPTP–binding properties of Slitrk mutations. Representative images of cell-surface–binding assays. HEK293T cells
expressing WT or mutant forms of HA-tagged Slitrk1 (A), Slitrk2 (B), or Slitrk4 (C) were incubated with 10 µg/ml control IgC or Ig-PTPδ, and then analyzed by
immunofluorescence imaging of Ig-fusion proteins (red) and HA antibodies (green). Percentages of the cells exhibiting the binding of Ig-PTPδ were as follows: WT
Slitrk1, 66.7%; Slitrk1[N400I], 32%; Slitrk1[T418S], 41%; Slitrk1[R584K], 62%; Slitrk1[S593G], 68.7%; WT Slitrk2, 71%; Slitrk2[R32L], 82%; Slitrk2[V89M], 81%;
Slitrk2[S549F], 68.8%; Slitrk2[S601P], 80%; Slitrk2[L626F], 76%; WT Slitrk4, 81%; Slitrk4[V206I], 24%; and Slitrk4[I578V], 22.2%. Note that a subset of Slitrk
mutants (Slitrk1[N400I], Slitrk1[T418S], Slitrk4[V206I] and Slitrk4[I578V]) exhibit reduced binding to Ig-PTPδ, paralleling their impaired surface transport (see
Figure 3). Scale bar, 10 µm (applies to all images).
USA). The normal distribution of the data was investigated
by p-values from Kolmogorov-Smirnov test (obtained
p-values > 0.05, except the data in Figures 6C and 10B).
Thus, these data were statistically evaluated using one-way
analysis of variance (ANOVA), using cell numbers (>10) or
the number of experiments (>3) as the basis for ‘n’. For the
Figures 6C and 10B, the data were statistically assessed using a
non-parametric Kruskal−Wallis test.
RESULTS
A variety of rare Slitrk point mutations have been found to
be associated with schizophrenia or OCD spectrum disorders
(Proenca et al., 2011; Ko, 2012; Um and Ko, 2013). Because one of
the aims of this study was to evaluate the functional consequences
of SLITRK gene mutations for neuropsychiatric disorders, we
focused on only non-synonymous, missense mutations in this
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FIGURE 5 | Retention of Slitrk mutant proteins in the cis-Golgi and ER in COS-7 cells. (A−C) Immunofluorescence staining of COS-7 cells demonstrates
cis-Golgi retention of a subset of mutants. COS-7 cells were transfected with WT or mutant forms of HA-tagged Slitrk1 (A), Slitrk2 (B), or Slitrk4 (C), and then
stained with anti-HA (green) and anti-GM130 (red) antibodies. Scale bar, 10 µm (applies to all images). (D) Quantification of the average intensity of GM130-positive
Slitrks. All data are shown as means ± SEMs (3∗p < 0.001; ANOVA with post hoc Tukey’s test; p-value of WT Slitrk1 vs Slitrk1[N400I] = 0.00053; p-value
of WT Slitrk1 vs. Slitrk1[T418S]= 0.000383; p-value of WT Slitrk2 vs. Slitrk2[V89M]= 1.83943E-7; p-value of WT Slitrk4 vs. Slitrk4[V206I]= 8.0637E-9; p-value of WT
(Continued)
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FIGURE 5 | Continued
Slitrk4 vs. Slitrk4[I578V] = 5.1018E-9). The numbers of cells counted were as follows: WT Slitrk1, n = 26; Slitrk1[N400I], n = 22; Slitrk1[T418S], n = 24;
WT Slitrk2, n = 24; Slitrk2[V89M], n = 27; WT Slitrk4, n = 19; Slitrk4[V206I], n = 22; and Slitrk4[I578V], n = 23. (E−G) Immunofluorescence staining of COS-7
cells demonstrates ER retention of mutants. COS-7 cells were transfected with WT or mutant forms of HA-tagged Slitrk1 (E), Slitrk2 (F), or Slitrk4 (G), together with
BFP-KDEL (red; pseudo-colored). The cells were then stained with anti-HA (green). Scale bar, 10 µm (applies to all images). (H) Quantification of the
average intensity of KDEL-positive Slitrks. All data are shown as means ± SEMs (∗p < 0.05, 3∗p < 0.001; ANOVA with post hoc Tukey’s test; p-value of WT
Slitrk1 vs. Slitrk1[N400I] = 0.000093; p-value of WT Slitrk1 vs. Slitrk1[T418S] = 0.036; p-value of WT Slitrk2 vs. Slitrk2[V89M] = 0.000712; p-value of WT Slitrk4 vs.
Slitrk4[V206I] = 0.000257; p-value of WT Slitrk4 vs. Slitrk4[I578V] = 0.000458). The numbers of cells counted were as follows: WT Slitrk1, n = 26; Slitrk1[N400I],
n = 24; Slitrk1[T418S], n = 22; WT Slitrk2, n = 17; Slitrk2[V89M], n = 23; WT Slitrk4, n = 22; Slitrk4[V206I], n = 22; and Slitrk4[I578V], n = 21.
study. Eleven missense mutations have previously been reported
to be linked to neuropsychiatric disorders (Zuchner et al.,
2006; Piton et al., 2011; Ozomaro et al., 2013). These include
N400I, T418S, R584K, and S593G in human Slitrk1; R32L,
V89M, S549F, S601P, and L626F in human Slitrk2; and V206I
and I578V in human Slitrk4 (Figures 1A–C). The L626F
mutation in human Slitrk2 also exists in other human Slitrks at
equivalent positions (Figure 1B), but none of the other residues
exhibit complete sequence identity across the six Slitrk members
(Figures 1A–C). Notably, all four mutated residues identified
in human Slitrk1 are unique to Slitrk1 (Figure 1A). However,
most of these residues are quite evolutionarily conserved among
various species, implying their possible functional significance
(Figures 1D–F). To draw inferences regarding the structural and
functional importance of these single amino acid substitutions,
we employed the widely used PolyPhen2 (Kumar et al., 2009),
PANTHER (Thomas and Kejariwal, 2004), SIFT (Adzhubei
et al., 2010), and MutationAssessor (Reva et al., 2011) software
packages (Table 1). Interestingly, none of the Slitrk missense
mutations that are the focus of this study were consistently
predicted to be either benign or have deleterious impacts on the
stability and function of human Slitrks by the four different in
silico prediction tools (Table 1).
Prediction of Structural Phenotypes
Produced by Slitrk Missense Mutations,
As Reflected in Protein Folding and
Three-Dimensional (3D) Structure
Notably, two Slitrk1 mutations (N400I and T418S) are located
in the LRR2 domain (Figure 1A). Crystal structure of human
Slitrk1 LRR2 indicated that the residue N400 of human Slitrk1
forms a weak hydrogen bond with an amino group of the main
chain of S375 and a hydroxyl group of the side chain of N376
on the neighboring loop (Figure 2). Therefore, mutating N400
to a nonpolar isoleucine (Ile) residue is likely to disrupt these
interactions, possibly causing misfolding and aberrant protein
trafficking (see below). The side chain of T418 in human Slitrk1
forms a hydrogen bond with a carboxyl group of the main chain
of E415 and is involved in hydrophobic interactions with I390,
F395, and F419 (Figure 2). Thus, a point mutation of T418 to
serine (T418S) is also expected to disrupt these hydrophobic
interactions. The other Slitrk1 mutations (R584K and S593G)
and Slitrk2 mutations (S601P and L626F) are located outside
major structural domains, consistent with the results of in silico
analyses (Figure 1A; Table 1). R32L in human Slitrk2 is located
immediately preceding the LRR1 domain (i.e., the terminal
residue of the signal peptide; Figure 1A). Point mutations in
human Slitrk2 (V89M or S549F) and human Slitrk4 (V206I or
I578V) were predicted to have little effect on the 3D structures of
individual Slitrks (Figure 2) (Um et al., 2014a).
Biochemical and Ligand-Binding
Phenotypes of Disease-Associated Slitrk
Missense Mutants
We next investigated the expression levels and intracellular
trafficking of Slitrk mutants in non-neuronal cells (Figure 3).
As is typically observed for numerous glycoproteins (Yim et al.,
2013), immunoblot analyses of HEK293T cells transfected with
expression vectors for HA-tagged, full-length Slitrks showed
that WT Slitrk proteins were detectable as two discrete
bands: approximately 75–100 kDa for Slitrk1 and Slitrk2,
and 100–110 kDa for Slitrk4 (Figure 3A). Total protein
expression levels of Slitrk point mutants were comparable
to those of the corresponding WT Slitrks (Figure 3A).
Strikingly, the mature protein levels of a subset of Slitrk1
mutants (N400I and T418S) and Slitrk4 mutants (V206I
and I578V) were significantly decreased (Figure 3A). The
upper band observed in lysates of Slitrk-expressing HEK293T
cells represents fully glycosylated mature protein species
that are resistant to Endo-H (which cleaves only immature
sugars attached in the endoplasmic reticulum, ER) and are
presumably presented to the cell surface, whereas the lower
band represents glycosylated immature protein species that are
sensitive to Endo-H and are undergoing processing in the
ER compartment (Figure 3B). Immunoblot analyses of WT
Slitrks treated with PNGase F, which removes all attached
N-linked oligosaccharides, showed a band shift (Figure 3B),
consistent with a previous report that Slitrks are highly
glycosylated (Yim et al., 2013). We next examined the surface
and intracellular protein levels of individual WT Slitrks and
Slitrk point mutants in HEK293T cells (Figures 3C–E). In
line with the biochemical data, two Slitrk1 mutants (N400I
and T418S) and two Slitrk4 mutants (V206I and I578V),
but not the other Slitrk mutants, displayed significantly
reduced surface expression levels with complete trapping
in intracellular compartment (Figures 3C–F). To reaffirm
findings of immunofluorescence analyses in HEK293T cells, we
performed biotinylation experiments. We found that the same
mutations in Slitrk1 (N400I and T418S) and Slitrk4 (V206I and
I578V) impaired the surface expression of the corresponding
protein (Figure 3G). We then performed binding assays
between recombinant Ig-fusion proteins of PTPδ (IgC-PTPδ)
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FIGURE 6 | Impaired dendritic targeting of Slitrk1[N400I], Slitrk1[T418S] and Slitrk2[V89M] mutants in cultured hippocampal neurons.
(A−B) Fluorescence images of hippocampal neurons transfected with wild-type (WT) HA-Slitrk1, HA-Slitrk1[N400I], HA-Slitrk1[T418S], WT HA-Slitrk2,
HA-Slitrk2[R32L], HA-Slitrk2[V89M], HA-Slitrk2[S549F], HA-Slitrk2[S601P] or HA-Slitrk2[L626F] at DIV10. The transfected neurons at DIV14 were
double-immunostained for antibodies against the somatodendritic marker MAP2 (green) and HA (red). Note that Slitrk1[N400I] and Slitrk1[T418S] are mainly
observed in the periphery of soma regions of the transfected neurons, but not in dendritic regions. Meanwhile, Slitrk2[V89M] exhibits decreased dendritic targeting.
Scale bar, 50 µm (applies to all images). (C) Dendritic targeting of WT HA-Slitrk1, HA-Slitrk1[N400I], HA-Slitrk1[T418S], WT HA-Slitrk2, HA-Slitrk2[R32L],
HA-Slitrk2[V89M], HA-Slitrk2[S549F], HA-Slitrk2[S601P], or HA-Slitrk2[L626F] in hippocampal neurons was quantified by measuring average intensity of HA
immunofluorescence in primary dendrites. The average intensity of Slitrk WT and mutants in soma region of the transfected neurons was also quantified. All data are
shown as means ± SEMs (2∗p < 0.01; 3∗p < 0.001; a non-parametric Kruskal−Wallis test; p-value of WT Slitrk1 vs. Slitrk1[N400I] = 0.001; p-value of WT Slitrk1 vs.
Slitrk1[T418S] < 0.001; p-value of WT Slitrk2 vs. Slitrk2[R32L] = 0.052; p-value of WT Slitrk2 vs. Slitrk2[V89M] = 0.000; p-value of WT Slitrk2 vs.
Slitrk2[S549F] = 0.178; p-value of WT Slitrk2 vs. Slitrk2[S601P] = 0.169; p-value of WT Slitrk2 vs. Slitrk2[L626F] = 0.284). ‘n’ denotes the number of neurons as
follows: WT Slitrk1, n = 16; Slitrk1[N400I], n = 19; Slitrk1[T418S], n = 16; WT Slitrk2, n = 16; Slitrk2[R32L], n = 14; Slitrk2[V89M], n = 14; Slitrk2[S549F], n = 13;
Slitrk2[S601P], n = 14; and Slitrk2[L626F], n = 13.
and HEK293T cells expressing HA-tagged Slitrks (Figure 4).
Recombinant IgC-PTPδ robustly bound to HEK293T cells
expressing various Slitrk mutants, except those expressing the
Slitrk1/4 mutants with impaired surface expression (Figures 4
and 3C–G). These data suggest that a subset of Slitrk point
mutations observed in neuropsychiatric patients causes improper
biochemical processing and abnormal cellular trafficking in non-
neuronal cells.
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FIGURE 7 | Impaired synaptogenic activity of a subset of Slitrk
mutants in cultured hippocampal neurons. (A−C) Representative images
of the heterologous synapse-formation activities of WT Slitrk and the indicated
point mutants in cultured hippocampal neurons. Neurons were cocultured
with HEK293T cells transfected with WT or the indicated mutant forms of
HA-Slitrk1 (A), HA-Slitrk2 (B), or HA-Slitrk4 (C) at DIV10. Neurons at DIV12
were then immunostained with antibodies against EGFP or HA (blue) and
synapsin (red). Scale bar, 10 µm (applies to all images). (D) Synapse-formation
activity in panels (A–C) was quantified by measuring the ratio of synapsin
(Continued)
FIGURE 7 | Continued
staining intensity (red) to HA/EGFP intensity (blue). All data are shown
as means ± SEMs (∗p < 0.05; 2∗p < 0.01; 3∗p < 0.001; ANOVA with
post hoc Tukey’s test; p-value of WT Slitrk1 vs. Slitrk1[N400I] = 0.00176;
p-value of WT Slitrk1 vs. Slitrk1[T418S] = 0.0497; p-value of WT Slitrk1 vs.
Slitrk1[R584K] = 0.959; p-value of WT Slitrk1 vs. Slitrk1[S593G] = 0.434;
p-value of WT Slitrk2 vs. Slitrk2[R32L] = 0.818; p-value of WT Slitrk2 vs.
Slitrk2[V89M] = 0.957; p-value of WT Slitrk2 vs. Slitrk2[S549F] = 0.956;
p-value of WT Slitrk2 vs. Slitrk2[S601P] = 0.984; p-value of WT Slitrk2 vs.
Slitrk2[L626F] = 0.987; p-value of WT Slitrk4 vs. Slitrk4[V206I] = 0.00062; and
p-value of WT Slitrk4 vs. Slitrk4[I578V] = 1.5112E-7). ‘n’ denotes the number
of HEK293T cells as follows: Control, n= 14; WT Slitrk1, n= 14; Slitrk1[N400I],
n = 12; Slitrk1[T418S], n = 14; Slitrk1[R584K], n = 14; Slitrk1[S593G], n = 21;
WT Slitrk2, n= 12; Slitrk2[R32L], n= 10; Slitrk2[V89M], n= 10; Slitrk2[S549F],
n = 15; Slitrk2[S601P], n = 15; Slitrk2[L626F], n = 15; WT Slitrk4, n = 17;
Slitrk4[V206I], n = 13; and Slitrk4[I578V], n = 15.
Cellular Phenotypes of
Disease-Associated Slitrk Missense
Mutants
The immunocytochemical results clearly indicate that a subset of
Slitrk point mutants exhibits abnormal trafficking and decreased
surface expression (Figure 3). To independently corroborate this
interpretation, we analyzed the subcellular distribution of Slitrk
mutants using immunofluorescence microscopy (Figure 5). First,
we transfected COS-7 cells with WT or mutant Slitrks, and
stained them with antibodies against HA and GM130 (a cis-
Golgi marker) (Figures 5A–C). Consistent with the biochemical
data, a subset of Slitrk mutant proteins showed distinct patterns
of colocalization with GM130 (Figures 5A–C). The average
fluorescence intensity of GM130-positive Slitrk mutant proteins
was significantly increased than that of WT (Figure 5D). We also
cotransfected COS-7 cells with WT and mutant Slitrks, together
with a blue fluorescent protein-fused KDEL construct to visualize
the ER compartment (Figures 5E–G). Again, we found that Slitrk
mutant proteins showed overlapping colocalization with BFP-
KDEL (Figure 5H). These data indicate that Slitrk mutants are
in general intracellularly trapped in the cis-Golgi and/or ER in
non-neuronal cells. To ensure that these Slitrk mutations had
a similar effect on the transport of Slitrks out of the ER in
neurons, we transfected cultured hippocampal neurons with WT
or mutant Slitrks and analyzed them by immunocytochemistry
(Figure 6). HA-tagged WT Slitrk1 and Slitrk2 were efficiently
transported into dendrites, whereas HA-Slitrk1[N400I], HA-
Slitrk1[T418S] or HA-Slitrk2[V89M] were either completely
retained in the cell body of transfected neurons or displayed
markedly impaired trafficking into dendrites (Figures 6A,B),
as judged by the comparable immunofluorescence signals
in the soma of transfected neurons (Figure 6C). Notably,
other Slitrk2 mutants were targeted to dendrites similarly to
Slitrk2 WT (Figures 6B,C). These observations suggest that
the surface transport deficiency observed in heterologous cells
(except for HA-Slitrk2[V89M]) is similarly recapitulated in
cultured hippocampal neurons. We were unable to examine the
distribution of WT or mutant forms of HA-Slitrk4 because the
expression levels of these constructs were too low to be evaluated
in this type of analysis.
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FIGURE 8 | Impaired regulation of synapse density by a subset of Slitrk mutants in cultured hippocampal neurons. (A) Cultured hippocampal neurons
were transfected with a lentiviral vector expressing sh-Control, sh-Slitrk1, sh-Slitrk2 or sh-Slitrk4, or coexpressing the indicated sh-Slitrk vector and corresponding
shRNA-resistant Slitrk vectors at DIV8 and analyzed at DIV14 by double-immunofluorescence staining with antibodies to EGFP (green) and synapsin (red). Scale bar,
5 µm (applies to all images). (B,C) Summary data showing the effects of Slitrk molecular replacement in neurons on synapsin puncta density (B) and synapsin
puncta size (C). More than three dendrites per transfected neuron were analyzed and group-averaged. All data shown are means ± SEMs (∗p < 0.05; 2∗p < 0.01;
3∗p < 0.001; ANOVA with post hoc Tukey’s test; p-value of sh-Control vs. sh-Slitrk1 = 0.029; p-value of sh-Control vs. sh-Slitrk1+WT Slitrk1 = 0.99; p-value of
sh-Control vs. sh-Slitrk1+Slitrk1[N400I] = 0.004; p-value of sh-Control vs. sh-Slitrk1+Slitrk1[T418S] = 0.049; p-value of sh-Control vs. sh-Slitrk2 = 0.039; p-value
of sh-Control vs. sh-Slitrk2+WT Slitrk2 = 0.99; p-value of sh-Control vs. sh-Slitrk2+Slitrk2[V89M] = 0.0093; p-value of sh-Control vs. sh-Slitrk4 = 0.00075; p-value
of sh-Control vs. sh-Slitrk4+WT Slitrk4 = 0.877; p-value of sh-Control vs. sh-Slitrk4+Slitrk4[V206I] = 0.003; and p-value of sh-Control vs.
sh-Slitrk4+Slitrk4[I578V] = 0.008). ‘n’ denotes the number of neurons as follows: sh-Control, n = 16, sh-Slitrk1, n = 14, sh-Slitrk1+WT Slitrk1, n = 14;
sh-Slitrk1+Slitrk1[N400I], n = 14; sh-Slitrk1+Slitrk1[T418S], n = 14; sh-Slitrk2, n = 13; sh-Slitrk2+WT Slitrk2, n = 13; sh-Slitrk2+Slitrk2[V89M], n = 13;
sh-Slitrk4, n = 17; sh-Slitrk4+WT Slitrk4, n = 15; sh-Slitrk4+Slitrk4[V206I], n = 15; and sh-Slitrk4+Slitrk4[I578V], n = 15.
Neuronal Phenotypes of
Disease-Associated Slitrk Missense
Mutants
Slitrks were previously shown to trigger presynaptic
differentiation when expressed in heterologous cells and
cocultured in contact with axons (Takahashi et al., 2012; Yim
et al., 2013). To test whether the surface transport-deficient
Slitrk mutants showed differences in presynaptic differentiation-
inducing behavior compared with WT Slitrks, we performed
heterologous synapse-formation assays with HEK293T cells
expressing WT or mutant Slitrks (Figure 7). We found that,
whereas WT Slitrk1, Slitrk2, and Slitrk4 robustly recruited
synapsin clustering into the corresponding transfected HEK293T
cells, Slitrk1[N400I] and Slitrk1[T418S] as well as Slitrk4[V206I]
and Slitrk4[I578V] mutants were functionally inactive, as
expected by their lack of surface transport (Figures 7A,C; see
quantification in Figure 7D). None of the tested Slitrk2 mutants
exhibited altered synapse-inducing activity (Figures 7B,D).
To determine whether the surface transport-impairing Slitrk
mutations also compromised the ability of WT Slitrk proteins to
promote synapse formation in cultured neurons, we introduced
Slitrk isoform-specific knockdown (KD) vectors into cultured
hippocampal neurons at 8 days in vitro (DIV8), and stained
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FIGURE 9 | Characterization of the Slitrk1[V85M] mutant in heterologous synapse-formation assays and transfected neurons. (A) Surface expression
analysis of HEK293T cells expressing HA-tagged Slitrk1[V85M]. Transfected cells were immunostained with mouse anti-HA antibodies (red) and detected with
Cy3-conjugated anti-mouse secondary antibodies under non-permeabilized conditions, followed by permeabilization of cells. Cells were then stained first with rabbit
anti-HA antibodies (green) and then with FITC-conjugated anti-rabbit secondary antibodies. Scale bar, 10 µm (applies to all images). (B,C) Representative images
(B) and summary graph (C) of heterologous synapse-formation activities of WT Slitrk1 and Slitrk1[V85M]. Neurons were stained with antibodies against HA (blue;
pseudo-colored) and synapsin (red). Scale bar, 10 µm (applies to all images). ‘n’ denotes the number of HEK293T cells analyzed: WT Slitrk1, n = 13; and
Slitrk1[V85M], n = 12. (D) Fluorescence images of hippocampal neurons transfected with WT HA-Slitrk1 or HA-Slitrk1[V85M], at DIV8. After 48 h (DIV10), the
transfected neurons were double-immunostained for antibodies against the somatodendritic marker MAP2 (green) and HA (red). Note that Slitrk1[V85M] exhibits
decreased dendritic targeting. Scale bar, 50 µm (applies to all images). (E) Dendritic targeting of WT HA-Slitrk1 or HA-Slitrk1[V85M] in hippocampal neurons was
quantified by measuring fluorescent intensity (HA) in primary dendrites. All data are shown as means ± SEM (2∗p < 0.01; Student’s t-test; p-value = 0.00215).
‘n’ denotes the number of neurons as follows: WT Slitrk1, n = 15 and Slitrk1[V85M], n = 13. (F,G) Representative images (F) and summary graph (G) of neuron
transfection assays with a lentiviral vector expressing sh-Control, sh-Slitrk1, or coexpressing sh-Slitrk1 and the indicated shRNA-resistant Slitrk1 vectors at DIV8 and
analyzed at DIV14 by double-immunofluorescence staining with antibodies to EGFP (green) and synapsin (red). Scale bar, 5 µm (applies to all images). All data are
shown as means ± SEMs (3∗p < 0.001; ANOVA with post hoc Tukey’s test; p-value of sh-Control vs. sh-Slitrk1 = 0.000411; p-value of sh-Control vs.
sh-Slitrk1+WT Slitrk1 = 0.991; and p-value of sh-Control vs sh-Slitrk1+Slitrk1[V85M] = 2.74E−7). ‘n’ denotes the number of neurons quantified as follows:
sh-Control, n = 15, sh-Slitrk1, n = 15, sh-Slitrk1+WT Slitrk1, n = 15; and sh-Slitrk1+Slitrk1[V85M], n = 17.
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FIGURE 10 | The effect of the Slitrk1[N400I] and Slitrk1[T418S] mutants on neurite outgrowth in cultured hippocampal neurons. (A) Representative
images of DIV6 hippocampal neurons transfected with WT HA-Slitrk1, HA-Slitrk1[N400I], or HA-Slitrk1[T418S] at DIV3. Scale bar, 50 µm (applies to all images).
(B) Quantification of total neurite length per hippocampal neuron at DIV6. All data are shown as means ± SEMs (2∗p < 0.01; a non-parametric Kruskal−Wallis test;
p-value of Control vs. WT Slitrk1 = 0.003; p-value of Control vs. Slitrk1[N400I] = 0.0634; p-value of Control vs. Slitrk1[T418S] = 0.300). ‘n’ denotes the number of
neurons as follows: Control, n = 15, WT Slitrk1, n = 16, Slitrk1[N400I], n = 14; and Slitrk1[T418S], n = 14.
the transfected neurons with anti-EGFP and anti-synapsin
antibodies at DIV14 (Figure 8). As previously reported (Yim
et al., 2013), single KD of Slitrk1, Slitrk2, or Slitrk4 significantly
decreased the linear density of synapsin clusters (Figures 8A,B).
Expression of short hairpin RNA (shRNA)-resistant forms
of WT Slitrk1, Slitrk2, or Slitrk4 completely rescued these
deficits in the numbers of synapsin clusters (Figures 8A,B).
Similar to the results of heterologous synapse-formation assays,
expression of shRNA-resistant Slitrk1 mutants (N400I or
T418S) or Slitrk4 mutants (V206I or I578V) failed to reverse
the reduction in the density of synapsin clusters induced by
knockdown of Slitrk1 or Slitrk4 (Figures 8A,B). Strikingly,
expression of the Slitrk2[V89M] mutant, which showed total
expression levels, surface transport, and synapse-inducing
properties comparable to those of WT Slitrk2, did not rescue
the Slitrk2 KD-induced deficit in the numbers of synapsin
clusters, likely due to impaired dendritic targeting in neurons
(Figures 8A,B and 3). Since the valine residue at position 89 in
human Slitrk2 is also found Slitrk1, -3 and -4 (but not Slitrk5
and- 6; Figure 1B), we introduced a similar point mutation
into human Slitrk1 (Slitrk1[V85M]) and examined whether
this artificially generated Slitrk1 mutant behaves similarly
to Slitrk2[V89M] (Figure 9). We found that Slitrk1[V85M]
showed surface expression levels and synaptogenic activity
comparable to those of WT Slitrk1 (Figures 9A–C), but
exhibited decreased dendritic targeting in hippocampal
neurons (Figures 9D,E). Moreover, Slitrk1[V85M] showed
impaired synapse-promoting activity when expressed in Slitrk1-
deficient neurons (Figures 9F,G). These data suggest that
different Slitrk variants found in patients with neuropsychiatric
disorders may manifest distinct cellular readouts, compounding
the enormous complexity at both cellular and behavioral
levels.
DISCUSSION
The ‘synaptopathy’ hypothesis has been dominant in the
neuroscience field since the term was coined, aided in part by
the rapid advent of high-resolution human genetic sequencing
technologies (Brose et al., 2010). Various classes of synaptic
genes have been associated with a range of neuropsychiatric
and neurodevelopmental disorders, particularly in the case of
ASDs and schizophrenia, although most copy number variants
are rarely found in patients with these disorders (Glessner et al.,
2012; Malhotra and Sebat, 2012). Surprisingly, similar genetic
pathways have often been found to be linked to phenotypically
distinct outcomes, confounding the interpretation of genetic
approaches (Marshall and Scherer, 2012). Specifically, synaptic
adhesion molecules and their associated scaffold proteins, such
as neurexin-1α, neuroligin-4 and Shank3, are among the few
synaptic genes that are frequently identified as causative factors
for ASDs and schizophrenia (Sudhof, 2008; Won et al., 2013;
de la Torre-Ubieta et al., 2016). However, how these disease-
susceptible genes cause the associated disorders has only recently
begun to be understood.
In the present study, we employed a series of functional
approaches to ask whether Slitrk mutations identified in
schizophrenia, trichotillomania or OCDs alter the biochemical,
cellular and synaptic processes that are mediated by WT Slitrk
proteins. We found that a subset of Slitrk1, Slitrk2, and Slitrk4
missense mutants exhibit common and distinct phenotypes in a
variety of assays, results that often differed from those predicted
by algorithm-based in silico analyses (Table 1). Indeed, many
of these mutations did not induce any prominent alterations in
the properties of Slitrk proteins, although it is possible that the
functional assays employed in the current study were unable to
capture all aspects of Slitrk function. Thus, our data underscore
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the importance of experimentally testing whether candidate
mutants identified based on human genetics are physiologically
significant. In exploring whether candidate human mutations
have distinctive phenotypes at molecular and cellular levels, we
focused on two Slitrk1 missense mutations (N400I and T418S),
a single Slitrk2 mutation (V89M), and two Slitrk4 mutations
(V206I and I578V).
Our data suggest that the respective disorder phenotypes
observed in patients with Slitrk mutations are at least partly
caused by Slitrk dysfunctions, based on the following evidence:
(1) most of the mutated residues in Slitrk1, Slitrk2, and
Slitrk4 are evolutionarily conserved across various species,
although only a few are also found across all six Slitrk family
members; (2) most of the substitutions caused retention in
intracellular compartments, such as the ER and cis-Golgi, with
an accompanying loss of normal Slitrk glycosylation patterns; (3)
none of the substitutions perturbed ligand-binding properties,
judging from previously determined complex structures; and
(4) all but one of the substitutions abolished the effects of
Slitrks on synapse formation, with Slitrk2[V89M] uniquely
exhibiting the ability to trigger presynaptic differentiation.
Notably, none of the Slitrk mutations described here abolished
binding to LAR-RPTPs per se. However, a majority of Slitrk
mutations are positioned in the LRR2 domain of Slitrks
(Figure 1); thus, the possibility that LRR2 domain-mediated
molecular interaction(s) might be influenced by Slitrk mutations
cannot be excluded at this point. At present, precisely how
Slitrks promote distinct types of synapse development in an
isoform-dependent manner remains to be elucidated (Yim
et al., 2013), but it would be worthwhile investigating the
relationship between altered synapse numbers induced by
Slitrk missense mutations and the development of associated
neuropsychiatric disorders in follow-up studies. Intriguingly,
Slitrk family proteins resemble neuroligin family proteins
in many ways (Brose, 2013). For example, the action of
Slitrk3 at inhibitory synapses is phenomenologically analogous
to that of neuroligin-2, whereas the effects of the other
Slitrk family members are related to those of neuroligin-
1. However, more rigorous analyses should be undertaken
to provide a complete understanding of how synaptogenic
adhesion molecules operate cooperatively, competitively, or
both.
Most Slitrk substitutions represent loss-of-function mutations
that perturb the normal folding and glycosylation of Slitrks,
seemingly similar to the situation previously described for
the R87W substitution in human neuroligin-4 and D1129H
substitution in human CNTNAP2 (Zhang et al., 2009; Falivelli
et al., 2012). The V89M substitution is somewhat analogous
to previous descriptions of the R451C substitution in human
neuroligin-3 (Comoletti et al., 2004; De Jaco et al., 2010)
in that Slitrk2[V89M] protein retained WT-like presynapse-
inducing activity (Figure 7). However, this substitution acted
as dominant-negative mutation, abolishing the ability of
Slitrk2 to promote synapse formation in transfected neurons
because of its ability to alter the synaptic properties of
neurons (Figure 8). Intriguingly, our preliminary analyses
indicate a weak correlation between dendritic spine density
and synapsin puncta density in Slitrk-deficient neurons (Data
not shown). Further investigation using membrane-anchored
GFP plasmid to more accurately visualize the dendritic
spines would be required to solve the seemingly discrepancy
between postsynaptic spine density and presynaptic marker
density.
Currently, we have no insight into how the V89M
substitution causes inactivation of Slitrk2 function, but a
similar valine-to-methionine mutation was previously described
for BDNF (brain-derived neurotrophic factor) (Bath and
Lee, 2006; Chen et al., 2006). The human BDNF[V66M]
polymorphism, which is associated with altered dendritic
trafficking of BDNF mRNA, changes in hippocampal volume,
impaired hippocampal-dependent memory and NMDA-receptor
dependent synaptic plasticity, and extinction of conditioned
aversive memory, has been implicated in anxiety disorders
(Chiaruttini et al., 2009; Yu et al., 2009; Ninan et al., 2010).
The pathophysiological mechanism postulated for the effect
of this BDNF mutation is that sortilin directly interacts with
WT BDNF, but not BDNF[V66M], in secretory granules and
controls the pathway that regulates its secretion in neurons
(Chen et al., 2005). However, Slitrk2[V89M] does not block
the transport of Slitrk2 protein to the cell surface; thus, it
is conceivable that other mechanism(s) may operate in this
case. Slitrk1[N400I] was previously shown to be unable to
stimulate neurite outgrowth (Ozomaro et al., 2013), and the
current study also found that its glycosylation, surface transport,
and synaptogenic activities were impaired (Figures 3–8).
In contrast, Slitrk1[T418S] was not previously examined,
because it was frequently detected in individuals without
OCDs and thus was considered to be functionally tolerated
in the general population (Ozomaro et al., 2013). However,
our data clearly suggested that the T418S mutation also
abolishes the surface transport of Slitrk1 proteins, possibly by
impairing glycosylation patterns, similar to the biochemical
and cellular phenotypes of the N400I mutation. More
intriguingly, the Slitrk1[T418S] mutation also compromised
the enhanced neurite outgrowth activity shown by Slitrk1 WT
(Figure 10).
Apart from the unique action of the Slitrk2 V89M mutation,
the other Slitrk1, Slitrk2, and Slitrk4 mutations described
in the current study have features in common that are
typical of loss-of-function mutations, consistent with the
phenotypes of Slitrk KD in cultured hippocampal neurons
(Yim et al., 2013). Remarkably, Slitrk1-knockout (KO) mice
exhibit elevated anxiety-like behaviors that are attributable
to increased norepinephrine levels, and administration of the
centrally acting adrenergic agonist clonidine has been shown
to normalize these behaviors (Katayama et al., 2010). However,
the core symptoms of Tourette syndrome and trichotillomania,
such as self-grooming, were not reported in Slitrk1-KO mice
(Katayama et al., 2010). In the case of neuroligin-3, the R451C
mutation exhibits distinct gain-of-function synaptic phenotypes
compared with neuroligin-3-KO mice, but both neuroligin-3
R451C knock-in (KI) and KO also impair tonic endocannabinoid
signaling in specific interneuron-type synapses (Foldy et al.,
2013). Thus, a worthwhile task would be to compare the
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behavioral, physiological, and circuit phenotypes of Slitrk-KI
mice harboring some of the point mutations with altered Slitrk
functions described in the current study with those obtained from
Slitrk-KO mice. These approaches hold the potential of unveiling
more detailed pathophysiological mechanisms underlying Slitrk-
associated neuropsychiatric disorders.
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